8/18/2004

GlaxoSmithKline reportedly has abandoned a court fight in China to protect its patent on the diabetes drug, Avandia, apparently fearing it had little chance of winning. GSK holds the basic patent for Avandia, but Chinese generic firms have challenged patents for different doses and versions of the drug, known as "salts." The move follows China's decision to strip Pfizer's Viagra patent in the country, an action roundly condemned by foreign pharmaceutical firms that hope to remain in China's growing market for drugs.

Related Summaries